Browse 16 Paraganglioma Medical Studies Across 139 Cities
1 Phase 3 Trial · 223 Paraganglioma Clinics
What Are Paraganglioma Clinical Trials?
Paraganglioma is a form of neuroendocrine tumor. The formation of this tumor is on the patient's adrenal glands' outer nerves and blood vessels. These glands make hormones that are responsible for controlling several body functions. Paraganglioma is also known as extra-adrenal pheochromocytomas. The condition is progressive, and nearly 35 to 50 percent of paragangliomas spread to other body parts. Some people may experience symptoms while others may not. Symptoms of paraganglioma include:
Paraganglioma clinical trials are studies conducted to find novel treatments and their efficacy. They help discover the best ways to identify, screen, and treat the condition.
Why Is Paraganglioma Being Studied Through Clinical Trials?
Paraganglioma is a rare condition affecting two out of every one million people. Though most common in adults aged 30 to 50, paraganglioma can also occur in children. Nearly 10 percent of paraganglioma cases in the US occur in young children.
Hence, paraganglioma clinical trials are necessary to develop quality health outcomes for those with the condition.
Furthermore, in most cases, the exact cause of paraganglioma is unknown. It can occur randomly. However, only 25 percent of the cases were associated with hereditary conditions like VHL, MEN2A or MEN2B, and NF1.
Therefore, paraganglioma clinical trials are crucial to gain more insights into paraganglioma and finding the underlying causes, prevention techniques, and cures for improving the patients' quality of life.
What Are the Types of Treatments Available for Paraganglioma?
The treatment for paraganglioma is determined after taking into account multiple factors:
Treatments may include (separate or a combination of):
What Are Some Recent Breakthrough Clinical Trials for Paraganglioma?
2021: The use of immunotherapy treatment in malignant pheochromocytomas/paragangliomas: This report comprehensively details immunotherapy usage and its efficacy in managing paragangliomas. The case featured a 60-year-old woman with a malignant pheochromocytoma. Due to the critical location of the tumor, radiation therapy was not feasible. She started with immunotherapeutic agents. The therapy decreased tumor size while improving the quality of her life. The patient tolerated the treatment and exhibited progression-free survival.
2022: Treatment of Malignant Pheochromocytoma/Paraganglioma With Cyclophosphamide, Vincristine, and Dacarbazine-Eighteen patients with paraganglioma were treated using vincristine, cyclophosphamide, and dacarbazine. These medications were combined to create an effective treatment with chemotherapy. This combination produced impressive results with significant improvement in the patients' symptoms with paraganglioma.
Who Are Some of the Key Opinion Leaders/Researchers/Institutions Conducting Paraganglioma Clinical Trial Research?
It is a non-profit organization dedicated to creating awareness of paraganglioma through advocacy and research. The organization has been serving the community for more than 15 years.
The institute provides the best treatments to children and adults with cancer. It also performs research and clinical trials with a mission to discover cures with the highest level of efficacy and safety.